Skip to main content
. 2016 Feb 15;7(1):117–124. doi: 10.4291/wjgp.v7.i1.117

Table 2.

Jejunal and ileal neuroendocrine tumors treatment

Jejunal and ileal NETs – surgical treatment
Without metastasis, all sizes Surgical resection with wide lymphadenectomy + search for other lesions
With liver metastases Attempt curative surgery; intraoperative ultrasonography should be performed for detection of all liver metastases
If patient not suitable for curative resection, palliative surgery should be considered to prevent complications attributable to the tumor mass
Jejunal and ileal NETs – farmacological treatment
Functional jejunal-ileal NETs 1st line: Somatostatin analogs (symptomatic treatment and tumor growth stabilization)
2nd line: Interferon-α
Well-differentiated NETs Systemic chemotherapy not recommended
Poorly differentiated tumors Combination chemotherapy – variable duration disease remission
mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results
Metastatic or inoperable disease Peptide receptor radionuclide therapy
When all other treatment options fail
If positive Octreoscan

NETs: Neuroendocrine tumors; VEGF: Vascular endothelial growth factor.